Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1)

Biochemical Pharmacology

Volumn 72, Issue 2, 2006, Pages 145-155

  Maki, Nazli ^a   Dey, Saibal ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

125I iodoarylazidoprazosin (or 125I IAAP); Flupentixol; Multidrug resistance; Phenothiazine; Thioxanthene

Indexed keywords

CYCLOSPORIN A; FLUPENTIXOL; GLYCOPROTEIN P; PHENOTHIAZINE DERIVATIVE; THIOXANTHENE DERIVATIVE; VINBLASTINE;

ALLOSTERISM; ARTICLE; BINDING SITE; MEMBRANE TRANSPORT; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

ALLOSTERIC REGULATION; ANIMALS; AZIDES; CHROMATOGRAPHY, AFFINITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUPENTHIXOL; HUMANS; P-GLYCOPROTEIN; PHENOTHIAZINES; PRAZOSIN; XANTHINES;

EID: 33744942933     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.04.008     Document Type: Article

References (42)

1. Ueda K., Cornwell M.M., Gottesman M.M., Pastan I., Roninson I.B., Ling V., et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141 (1986) 956-962
2. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39 (1999) 361-398
3. Chen C.-j., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47 (1986) 381-389
4. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62 (1993) 385-427
5. Loo T.W., and Clarke D.M. Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J Biol Chem 269 (1994) 7750-7755
6. Loo T.W., and Clarke D.M. Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J Biol Chem 270 (1995) 21449-21452
7. Schinkel A.H., Kemp S., Dolle M., Rudenko G., and Wagenaar E. N-glycosylation and deletion mutants of the human P-glycoprotein. J Biol Chem 268 (1993) 7474-7481
8. Loo T.W., and Clarke D.M. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J Biol Chem 276 (2001) 36877-36880
9. Loo T.W., and Clarke D.M. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil MTS-verapamil. J Biol Chem 276 (2001) 14972-14979
10. Raviv Y., Pollard H.B., Bruggemann E.P., Pastan I., and Gottesman M.M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265 (1990) 3975-3980
11. Bruggemann E.P., Germann U.A., Gottesman M.M., and Pastan I. Two different regions of P-glycoprotein are photoaffinity labeled by azidopine. J Biol Chem 264 (1989) 15483-15488
12. Morris D.I., Greenberger L.M., Bruggemann E.P., Cardarelli C.O., Gottesman M.M., Pastan I., et al. Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. Mol Pharmacol 46 (1994) 329-337
13. Greenberger L.M., Lisanti C.J., Silva J.T., and Horwitz S.B. Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b. J Biol Chem 266 (1991) 20744-20751
14. Greenberger L.M. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J Biol Chem 268 (1993) 11417-11425
15. Dey S., Ramachandra M., Pastan I., Gottesman M.M., and Ambudkar S.V. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94 (1997) 10594-10599
16. Ford J.M. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A (1996) 991-1001
17. Tsuji A., Tamai I., Sakata A., Tenda Y., and Terasaki T. Restricted transport of Cyclosporin-A across the blood brain barrier by a multidrug transporter, p-glycoprotein. Biochem Pharmacol 46 (1993) 1096-1099
18. Saeki T., Ueda K., Tanigawara Y., Hori R., and Komano T. Human P-Glycoprotein transports Cyclosporin-A and FK506. J Biol Chem 268 (1993) 6077-6080
19. Dey S., Ramachandra M., Pastan I., Gottesman M.M., and Ambudkar S.V. Photoaffinity labeling of human P-glycoprotein: effect of modulator interaction and ATP hydrolysis on substrate binding. Methods Enzymol 292 (1998) 318-328
20. Dey S., Hafkemeyer P., Pastan I., and Gottesman M.M. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. Biochemistry 38 (1999) 6630-6639
21. Martin C., Berridge G., Mistry P., Higgins C., Charlton P., and Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128 (1999) 403-411
22. Martin C., Berridge G., Higgins C.F., and Callaghan R. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br J Pharmacol 122 (1997) 765-771
23. Boer R., Dichtl M., Borchers C., Ulrich W.R., Marecek J.F., Prestwich G.D., et al. Reversible labeling of a chemosensitizer binding domain of p-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor. Biochemistry 35 (1996) 1387-1396
24. Ferry D.R., Malkhandi P.J., Russell M.A., and Kerr D.J. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49 (1995) 1851-1861
25. Maki N., Hafkemeyer P., and Dey S. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 278 (2003) 18132-18139
26. Maki N., Moitra K., Silver C., Ghosh P., Chattopadhyay A., and Dey S. Modulator-induced interference in the functional cross talk between the substrate and the ATP sites of human P-glycoprotein. Biochemistry 45 (2006) 2739-2751
27. Ramachandra M., Ambudkar S.V., Chen D., Hrycyna C.A., Dey S., Gottesman M.M., et al. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37 (1998) 5010-5019
28. Germann U.A., Willingham M.C., Pastan I., and Gottesman M.M. Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry 29 (1990) 2295-2303
29. Bailey JL. New York: Elsevier Publishing Co.; 1967. p. 340-41
30. Hrycyna C.A., Ramachandra M., Ambudkar S.V., Ko Y.H., Pedersen P.L., Pastan I., et al. Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites. J Biol Chem 273 (1998) 16631-16634
31. Germann U.A., Chambers T.C., Ambudkar S.V., Licht T., Cardarelli C.O., Pastan I., et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271 (1996) 1708-1716
32. Prozialeck W.C., and Weiss B. Inhibition of calmodulin by phenothiazines and related drugs: structure-activity relationships. J Pharmacol Exp Ther 222 (1982) 509-516
33. Prozialeck W.C. Interaction of quaternary phenothiazine salts with calmodulin. J Pharmacol Exp Ther 231 (1984) 473-479
34. Sachs C.W., Safa A.R., Harrison S.D., and Fine R.L. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 270 (1995) 26639-26648
35. Yang J.M., Chin K.V., and Hait W.N. Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res 56 (1996) 3490-3494
36. Szabo K., Bakos E., Welker E., Muller M., Goodfellow H.R., Higgins C.F., et al. Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity. J Biol Chem 272 (1997) 23165-23171
37. Schlemmer S.R., Yang C.H., and Sirotnak F.M. Functional modulation of multidrug resistance-related P-glycoprotein by Ca(2+)-calmodulin. J Biol Chem 270 (1995) 11040-11042
38. Ambudkar S.V., Lelong I.H., Zhang J.P., Cardarelli C.O., Gottesman M.M., and Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump-characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 89 (1992) 8472-8476
39. Schagger H., and von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166 (1987) 368-379
40. Fan D., Poste G., Seid C., Earnest L.E., Bull T., Clyne R.K., et al. Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol. Invest New Drugs 12 (1994) 185-195
41. Beltran P.J., Fan D., Fidler I.J., and O'Brian C.A. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem Pharmacol 53 (1997) 245-247
42. Hait W.N., and Aftab D.T. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol 43 (1992) 103-107